Candidate Information Name Available: Register for Free Title Antibody discovery and engineering, Cell therapy, Protein expres Target Location US-CT-New Haven Email Available with paid plan Phone Available with paid plan	20,000+ Fresh Resumes Monthly     View Phone Numbers     Receive Resume E-mail Alerts     Post Jobs Free     Link your Free Jobs Page     ... and much more Register on Jobvertise Free
Search 2 million Resumes Keywords: City or Zip:	Related Resumes Employee Relations Executive Chappaqua, NY Vice President Creative Director Stamford, CT Human Resources Office Services Mamaroneck, NY Presales Engineer Pre Sales Smithtown, NY Java Developer Full-Stack Hamden, CT Active Directory Red Hat Lindenhurst, NY Technology sales, SaaS, Cloud, Cybersecurity New Milford, CT

Candidate's Name , Ph.D, MSc.PHONE NUMBER AVAILABLE EMAIL AVAILABLE Linked in Google ScholarSUMMARYDemonstrated team leadership and molecular biological scientist with 20+ years of experience and expertise in the area of antibody discovery platform and engineering design; CRISPR-based perturbation technologies (knock in/knock out) and CRISPR-based platform development; Protein expression and purification including the optimization of secretion peptide; NGS sequencing and multi-layer Omics analysis; Oncology biotherapy and establishing biological modes for function identification and therapeutic evaluation. Vaccine development and its expression optimization. HIGH LIGHT TECHNIQUE SKILLS Antibody Discovery and Engineering Design: Hybridoma and HT single B cell monoclonal antibody (mAb) discovery platform and automation; VHH Phage display screening; VH and VL recovery and HT cloning; NGS and large-scale data analysis; Design and production of recombinant mAb, subtype switch, isotype switch, chimeric antibodies; engineered therapeutic antibody such as scFV, VHH, bi-Specific and Car-T; bioinformatics analysis of antibody sequencing data and structure using local or online software such as Geneious, Bioinformatics portal, Snap Gene, IgBlast. Gene Editing: CRISPR/Cas9/Csy4 multiple gene edition platform for the simultaneous knockout and knock in of multiple target genes using a single viral vector; streamlining gene editing processes using somatic cells and transform normal adult cell into carcer cells; targeting/off targeting analysis and genome wide gRNA design. Immunotherapy and Oncolytic Therapy: Strategy development; therapeutic bispecific nanobody design and expression; research and development of immunotherapy and oncolytic therapy of Melanoma, Colon and Ovarian cancers, contributing to advancements in cancer Immunotherapy treatment. Cell biology: Primary T/B /melanocytic cell/human tumor cell isolation/culture; cell line culture; Overexpressed or gene edited stable-cell line generation; proliferation assay; Cell toxicity assay, etc. Immunological assays: Multicolor flow cytometry; Immune cell sorting; Immune cell co-culture assay; ELISA Immunofluorescence (Confocal); Immunohistochemistry; H&E staining; Tunnel assay; Tissue microarray etc. Molecular biology/Biochemistry: Molecular cloning; Expression / shRNA / viral vector construction; Plasmid / siRNA/shRNA; transfections; Immunoprecipitation; Chromatin immunoprecipitation (ChIP) assay; RT-PCR; Western blot; protein purification; FPLC/HPLC, Mass-Spec; RNA related experiments: In vitro mRNA transcription and purification; Immunoprecipitation; Fluorescence In Situ Hybridization (FISH); In vitro RNA pull- down; RNA immunoprecipitation; In vitro RNA transcription; Cross link Immunoprecipitation (CLIP) etc. Bioinformatics and Data Analysis: Multi-omics data mining covered Genomic, Transcriptomic and Proteomic analysis for genotype and phenotype; MATLAB, Snap Gene, Geneious, GraphPad Prism, LIMS and Bioinformatics Portal; PowerPoint/Excel, Imaging (Image J, Photoshop, Illustrator). WORK EXPERIENCEEpigenoMax Therapeutics-Principal Investigator/Co-Founder, R&D of Innovation Antibody Drugs and Therapeutics, July, 2023  current, Farmington, CT Co-Founder of Epigenomax Therapeutics, Cooperation and grant proposal/submission; Perform the strategic development and design for cancer and Alzheimer disease (AD) therapies. Emphasize innovation drugs with precision targeting via engineered bi-specific nanobodies that recognize the disease cells. "Precision Molecular Surgery Knife, PMSK" has been patented by USPTO; Perform gene drug synthesis, analyze antibody sequences, design bi-specific nanobodies and caried out In Vitro studies. ABCAM  ILM Group Leader, Scientist, Antibody Discovery and Engineering Aug, 2021 - July, 2023, Branford, CT. Group Leader and project management, overseeing monoclonal antibody discovery and engineering for ILM (In house licensor monoclonal antibody project) group (6 scientists from China, UK and USA), more than 100 antibodies have been published for commercialization or for custom projects; Responsible for LIMs Tracker Maintenance and Updating of ILM projects timely to seamless communicate across Branches and Departments world wide of Abcam; Responsible for NGS Sequencing, large-scale data analysis and quality evaluation of purchased licensed antibodies of ILM project in ABCAM; Responsible for oversee and execute the HT screening, VH and VK recovery and HT cloning; Responsible for engineering design of antibodies of custom projects. Yale University Smilow Cancer Center - Scientist, Gene Edition Platform and Cell Therapy, April, 2019 - June 2021, New Haven, CT Developed CRISPER/Cas9/Csy4 multiple gene edition platform that integrates all in one step with high gene edition efficiency; Established triple gene (BrafV600E, Pten, and Cdk2a) edited cell lines using melanocytes from NOD mice; (In Vitro and Vivo assay); Cell Therapy: Involved in therapeutic study of NOD mice harbored with melanoma using FMOD and SOX2 knockout cells via IP injection and data has been published as co-authors; (Ex Vivo and In Vivo assay). In Vivo therapy of RNLS KO mice harbored with tumors using hormone 17-estradiol (E2). Caro Gen Corp - Senior Scientist, Project Leader, Cell Therapy and Vaccine Development June, 2017 - March, 2019 Farmington, CT Performed immunotherapy and oncolytic therapy using Virus-Like Vesicles (VLV) to treat colon and ovarian cancer animal models, discovered the oncolytic function of VLV and this discovery has been USPTO patented; Engineered the VLV vector by serotype switch of capsid proteins, armed VLV with IL12/PDL1/IL17RA, In Vitro and In Vivo therapeutic modeling. the data has been published as co-author; Developed HBV vaccine vector using VLV armed with HBV antigens (MHBs, pol and HBC), finished SBIR Phase II. Yale University - Associate Research Scientist, Cancer Molecular Mechanisms/ Biomarker Jan, 2010 - June, 2017 New Haven, CT Performed the studies of cancer molecular mechanisms and biomarker discovery including three cancer types of MKL, ESS, EOC. Discovered and identified the pathological function of OTT, Malat1 and fusion protein JAZF1/SUZ12 in carcinogenesis. More than 15 peer review papers published on first class journals such as "Blood, MCB, JBC, PNAS". EDUCATION Yale University - Postdoctoral Fellow, Molecular Biology Oct, 1997 - Dec, 1999 New Haven, CT, USA Central South University - Ph.D., Molecular Biology (Cancer Biology) Aug, 1992 - May, 1996 Changsha, China. The Chinese Academy of Sciences - MSc., Physical Chemistry Aug, 1989 - May, 1992, Shanghai, China. Hunan Normal University - BSc., Bachelor of Science, Biology 8,1983 - 6,1987 Changsha, China. SELECTED ACHIEVEMENTS AND REPUTATIONS US Provisional Patent, Inventor: Precision Molecular Surgery Knife (PMSK), USPTO, US63/571,157. US Provisional Patent, Inventor: A Novel Multiple CRISPR/Cas9/CSY4 Gene Editing Platform: All in Single Vector Both for Correction (HR) and Mutation (NHEG) Targeting, Processing. US Patent: Co-inventor: Compositions and Methods of Use of Oncolytic Viruses Like Vehicles, USPTO: US PHONE NUMBER AVAILABLE-A1. US Provisional Patent: Inventor: Trap and Wipe Coronavirus (TrWiCV) Via Genetic Engineered Streptococcus Thermophilus Bacteria. USPTO, US 63/024,370. Co-Chair of Cancer Biology Session: 9th American Biotechnology Congress, Sep, 2015, Orlando, Florida, USA. Grant received: Trans-Splicing of DNA in Endometrial Stromal Tissues (PI, Jeffrey Sklar, co-applicant, NCI, CA 85995, 2009. Grant received: Molecular Mechanism of Hematopoiesis (PI: Diane Krause, co-Applicant, Key Personnel, NIH DK053037, 2002). Grant received: C kappa Gene Knockout and Nasopharyngeal Carcinogenesis (NSFC, PI, 39600082, 1996). Editorial Board Membership: JBR Journal of Translational Diagnostics and Technology; Autin Journal of Clinical Pathology; Austin Journal of Pathology and Laboratory Medicine. SELECTED PUBLICATIONS Ma, X.Y., Wang, J, L., Wang, J.H. et al. Oncotarget. 8(3): 4062-4078. DOI: 10.18632/ oncotarget.13270. (2017) Ma, X.Y.,Wang, J.H., Wang. J.L., et al BMC Genomics 16 (676). DOI: 10.1186/sPHONE NUMBER AVAILABLE(2015); Ma, X.Y.,Renda M.J. et al. Mol. Cell. Biol. 27,3056. DOI: 10. 1128 /MCB. 01339-06 (2012). Li, H.,Ma,X.Y.,Wang, J.L., et al (2007). PNAS. USA 104, 20001-20006. DOI:10.1073/pnasPHONE NUMBER AVAILABLE; Li, H.,Wang, J.L., Ma, X.Y., et al (2009). Cell Cycle 8, 218-222. DOI: 10.4161/cc.8.2.7358 Ma, X.Y.,Wang, H., Ding B. et al. (2003).J. Biol. Chem. 278, PHONE NUMBER AVAILABLE DOI: 10.1074/jbc.M302105200; Ma, X.Y.,Husain T., Peng Hui., et al.(2002), Blood.100, 833-844. DOI: dx.doi.org /10.1182/blood. 100.3.833; REFERENCE Philip Gorman: Director, Twist Bioscience, Email: EMAIL AVAILABLE; Jay Chaplin: Head of Immunology and Interim Branford Site Head. Research and Innovation, ABCAM, 688 E Main St., Branford, CT 06405; Email: EMAIL AVAILABLE; Bijan Almassian: Co-Founder, Chairman and CEO, CarogenCorp, 200 Farmington Avenue, Farmington, CT: Tel: PHONE NUMBER AVAILABLE, Email: EMAIL AVAILABLE